Hobart

Seminar Abstract

Wednesday 21 April 2010, 11.30am (Tas time)
CSIRO Auditorium, Hobart

Tim Adams
Program Leader
Molecular & Cell Biology
CSIRO Division of Molecular and Health Technologies
Parkville, Victoria

Targeting the insulin-like growth factor pathway as a therapeutic strategy for the treatment of cancer

Traditionally, the insulin-like growth factors (IGF-I and IGF-II) have been viewed as key regulators of embryonic and post-natal growth in mammals. In recent years there has been a realisation that deregulated signalling through the IGF-I receptor, the principal cell-surface receptor mediating the activity of both IGF-I and IGF-II, is a key driver in the development/maintenance of malignancy in many different tumour types. As a result, the IGF-I receptor has become a major therapeutic target of interest for cancer. In this seminar, I will describe an alternative therapeutic strategy, whereby we have developed a human monoclonal antibody that binds and neutralises one of the ligands for this receptor, IGF-II, and our results to validate the anti-tumour activity of this antibody.

Seminar recording

[back]

Location:
CSIRO = Marine Laboratories Auditorium, Castray Esplanade, Hobart

For further information, or to schedule a seminar, contact:
To schedule a seminar, contact:
Clothilde Langlais, (Oceanographic seminars) CSIRO Marine and Atmospheric Research (03) 6232 5399
Natalie Kelly, (Biology/Modelling seminars) CSIRO Marine and Atmospheric Research 0438 452 483
Jillian Enraght-Moony, (seminar administrator) CSIRO Marine and Atmospheric Research (03) 6232 5320
Communications Manager, Antarctic Climate and Ecosystems CRC (03) 6226 2265
Margaret Hazelwood, Institute of Antarctic and Southern Ocean Studies (IASOS) University of Tasmania (03) 6226 2971

Last updated 11/05/10